Analysts have been eager to weigh in on the Healthcare sector with new ratings on UnitedHealth (UNH), Idexx Laboratories (IDXX) and Gilead Sciences (GILD).
UnitedHealth (UNH)
In a report released yesterday, A.J. Rice from Credit Suisse maintained a Buy rating on UnitedHealth, with a price target of $325.00. The company’s shares closed last Wednesday at $298.45, close to its 52-week high of $306.72.
According to TipRanks.com, Rice is a 4-star analyst with an average return of 5.5% and a 58.5% success rate. Rice covers the Healthcare sector, focusing on stocks such as Genesis Healthcare, Acadia Healthcare, and Community Health.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for UnitedHealth with a $327.77 average price target, representing a 10.2% upside. In a report issued on May 21, SunTrust Robinson also maintained a Buy rating on the stock with a $360.00 price target.
See today’s analyst top recommended stocks >>
Idexx Laboratories (IDXX)
Credit Suisse analyst Erin Wright maintained a Buy rating on Idexx Laboratories yesterday and set a price target of $300.00. The company’s shares closed last Wednesday at $295.18, close to its 52-week high of $302.99.
According to TipRanks.com, Wright is a 5-star analyst with an average return of 10.0% and a 65.9% success rate. Wright covers the Healthcare sector, focusing on stocks such as Phibro Animal Health, Quest Diagnostics, and Fulgent Genetics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Idexx Laboratories with a $280.00 average price target.
Gilead Sciences (GILD)
Credit Suisse analyst Evan Seigerman maintained a Sell rating on Gilead Sciences yesterday and set a price target of $64.00. The company’s shares closed last Wednesday at $73.83.
According to TipRanks.com, Seigerman is a 5-star analyst with an average return of 27.5% and a 71.8% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Satsuma Pharmaceuticals, Vertex Pharmaceuticals, and Aimmune Therapeutics.
Gilead Sciences has an analyst consensus of Hold, with a price target consensus of $79.23.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GILD:
